4D Molecular Therapeutics, Inc. Common Stock (FDMT) is a publicly traded Healthcare sector company. As of May 21, 2026, FDMT trades at $8.49 with a market cap of $437.29M and a P/E ratio of -3.28. FDMT moved +0.89% today. Year to date, FDMT is +16.03%; over the trailing twelve months it is +120.00%. Its 52-week range spans $2.24 to $12.34. Analyst consensus is strong buy with an average price target of $29.00. Rallies surfaces FDMT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for FDMT combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $8.49 |
| Market Cap | $437.29M |
| P/E Ratio | -3.28 |
| EPS | $-2.57 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.34 |
| 52-Week Low | $2.24 |
| Volume | 63 |
| Avg Volume | 0 |
| Revenue (TTM) | $88.24M |
| Net Income | $-160.90M |
| Gross Margin | 0.00% |
9 analysts cover FDMT: 0 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $29.00.